Previous 10 | Next 10 |
Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improveme...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an investor education webcast in conjunction ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 22nd Annual Needham Vi...
2023-03-21 11:06:46 ET The following slide deck was published by AtriCure, Inc. in conjunction with this event. For further details see: AtriCure (ATRC) Presents At Oppenheimer 33rd Annual Health Conference - Slideshow
AtriCure, Inc. (ATRC) Q4 2022 Earnings Conference Call February 21, 2023, 16:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference...
AtriCure press release ( NASDAQ: ATRC ): Q4 GAAP EPS of -$0.09 beats by $0.09 . Revenue of $88M (+20.2% Y/Y) beats by $0.1M . Adjusted EBITDA was positive for the fourth quarter 2022 at $6.0 million, compared to negative $2.1 million for fourth quarter of 2021. Adjus...
2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year 2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year 2022 International revenue of $53.2 million – an increase of 17.7% in 2022 AtriCure, Inc. ( Nasdaq:...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33 rd Annual Healthc...
Summary Cryoport has significantly underperformed the broader market over the past several months, largely due to poor earnings and cash flows. The company has excess cash on its books, but this doesn't make it a great prospect when you consider its continued profitability issues. A...
News, Short Squeeze, Breakout and More Instantly...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...